Deudomperidone
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT04026997)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
[2H]c1c([2H])c([2H])c2c([nH]c(=O)n2CCCN2CCC(n3c(=O)[nH]c4cc(Cl)ccc43)CC2)c1[2H]- Mol. weight
- 429.94 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594380 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06899217 | Phase 2 | Jan 29, 2025 | CinDome Pharma, LLC |
| NCT05832151 | Phase 2 | Mar 27, 2023 | CinDome Pharma, LLC |
| NCT04208698 | Phase 2 | Jan 2, 2020 | CinDome Pharma, LLC, CinRx Pharma |
| NCT04026997 | Phase 2 | Jul 31, 2019 | CinDome Pharma, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CinDome Pharma, LLC | For profit | 4 | 4 | 1 | 2019 |
| CinRx Pharma | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1